期刊文献+

“专利悬崖”背景下制药业的危机及我国的应对 被引量:9

On the Tactics to Deal with the “Patent Cliff”to Pharmaceuticals Industry in China
下载PDF
导出
摘要 全球制药行业近年迎来了重磅畅销药物专利到期的高峰,随之而来的则是制药企业因专利保护期届满而导致的销量和利润急剧下降的"专利悬崖"现象,给其带来了较大困境。这对仿制药制造大国的中国既是挑战也是机遇。运用Bolar例外规则,预先对仿制目标药进行研发和申请注册,综合运用知识产权策略和市场战略,是我国制药行业预防和应对"专利悬崖"的重要策略。 The global pharmaceutical industry faced with an expired patent peak of their blockbuster drug in recent years, followed by a dramatic fall of sales and profit, which is so called as "patent cliff". This phenomenon means both a challenge and an opportunity for China. Pharmaceutical manufacturers and researchers can use Bolar Exception System to research and register the target drug which will be copied beforehand. Using a combination of means, intellectual property strategy and marketing strategy, is an important strategy for pharmaeeutical industry in China to prevent and utilize the patent cliff.
机构地区 湘潭大学法学院
出处 《湘潭大学学报(哲学社会科学版)》 CSSCI 北大核心 2015年第6期80-84,共5页 Journal of Xiangtan University:Philosophy And Social Sciences
关键词 制药业 专利悬崖 知识产权策略 pharmacy patent cliff intellectual property strategy
  • 相关文献

参考文献14

  • 1Alexander Dennon & Erik Vollebregt. Can regenerative medicine save Big Parma's business model from tbe patent cliff[ J]. The Future Medicine, 2010,5 ( 5 ). 被引量:1
  • 2吴欣望:专利经济学[M].北京:社会科学文献出版社,2005. 被引量:1
  • 3Paula Tironi. Pharmaceutical Pricing: A Review of Proposals to Im- prove Access and Affordability of Prescription Drugs[ J]. Annals of Health Law, Winter 2010. 被引量:1
  • 4Alexander J. Kalter. Generic Drugs Post Novo Nordisk [ J ]. Ohio State Entrepreneurial Business Law ,Journal 2012. 被引量:1
  • 5赵贤,邵蓉.从药品基本专利和从属专利看我国医药企业专利战略[J].上海医药,2005,26(6):253-255. 被引量:9
  • 6袁真富.警惕"专利悬崖"下的利益深渊[N].中国知识产权报,2012-06-01(8). 被引量:1
  • 7Michael Johnsen , Proprietary Brands Boost Margins [ N ]. Drug Store News , October 25 2004. 被引量:1
  • 8林仲曼.个性化医疗:因人而异[EB/OL].环球企业家http://www. gemag, eom. en/12/29676_1, htm1,2012 -07. 被引量:1
  • 9Katherine R. Loft ,Health Care Reform and Its Impact on Health Care Merger and Acquisition Activity [ J ]. M&R Deal Strategies, Septem- ber 2011. 被引量:1
  • 10Paula Tironi. Pharmaceutical Pricing: a Review of Proposals to Im- prove Access and Affordability of Prescription Drugs[ J]. Annals of Health Law, Winter 2010. 被引量:1

二级参考文献27

  • 1文淑美.全球生物制药产业发展态势[J].中国生物工程杂志,2006,26(1):92-96. 被引量:43
  • 2中华人民共和国商务部.关于附条件批准辉瑞公司收购惠氏公司反垄断审查决定的公告[z].公告2009年第77号. 被引量:1
  • 3肖玮.哈药接手辉瑞在华部分动物疫苗业务[N].北京商报,2010-6-1. 被引量:1
  • 4http://www.biotech.org.cn/news/news/show.php?id=81370. [2010- 10-10]. 被引量:1
  • 5郭文.外企新药研发的中国热情[N].医药经济报,2010-1-25. 被引量:1
  • 6陈莺.惠氏:处方药与营养品“两条腿”并行[N].民营经济报,2006-5-26. 被引量:1
  • 7国家知识产权局.国际专利分类表[M].(第8版·2008.01修订).北京:知识产权出版社,2008:A部166.192,204.207,C部56-203,334-344,G部39-53. 被引量:1
  • 8丁萍,王进.生物技术并购继续高温[N].医药经济报,2010-8-18. 被引量:1
  • 9http://www.3156.cn/news/201009/55188.shtml.[2010-10-12]. 被引量:1
  • 10http://finance.yahoo.com/news/Pfizer-closes-purchase-ofapf4144591976.html?x=O&.v= 1. [2010-10-12]. 被引量:1

共引文献9

同被引文献120

引证文献9

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部